We’re proud to support Lipigon Pharmaceuticals as the CRO in this important clinical study — where the last patient has now completed the three-month follow-up.
This marks a key step toward understanding Lipisense®’s potential as a novel treatment for lipid disorders. With the patients three-month follow-up visits now finalized, the focus shifts to data analysis — with preliminary safety and efficacy results expected before the end of 2025.
A big thank you to all investigators, study teams, and Lipigon’s dedicated project group for their excellent collaboration throughout the trial.
At LINK Medical, we’re committed to helping innovators bring new therapies to patients through efficient, high-quality clinical execution across the Nordics and Europe.
🔗 Learn more about Lipigon’s announcement